|
1
|
Weigelt B, Peterse JL and van't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howlader NNA, Krapcho M, Garshell J,
Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
Mariotto A, et al: SEER Cancer Statistics Review, 1975–2013.
http://seer.cancer.gov/csr/1975_2013.
Accessed April 15, 2016
|
|
3
|
Westermarck J and Kahari VM: Regulation of
matrix metalloproteinase expression in tumor invasion. FASEB J.
13:781–792. 1999.PubMed/NCBI
|
|
4
|
Lee KS, Shin JS and Nam KS: Starfish
polysaccharides downregulate metastatic activity through the MAPK
signaling pathway in MCF-7 human breast cancer cells. Mol Biol Rep.
40:5959–5966. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang F, Hu M, Lei Q, Xia Y, Zhu Y, Song X,
Li Y, Jie H, Liu C, Xiong Y, et al: Nifuroxazide induces apoptosis
and impairs pulmonary metastasis in breast cancer model. Cell Death
Dis. 6:e17012015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li X, Kong X, Wang Y and Yang Q: BRCC2
inhibits breast cancer cell growth and metastasis in vitro and in
vivo via down-regulating AKT pathway. Cell Death Dis. 4:e7572013.
View Article : Google Scholar
|
|
7
|
Daniele A, Zito AF, Giannelli G, Divella
R, Asselti M, Mazzocca A, Paradiso A and Quaranta M: Expression of
metal-loproteinases MMP-2 and MMP-9 in sentinel lymph node and
serum of patients with metastatic and non-metastatic breast cancer.
Anticancer Res. 30:3521–3527. 2010.PubMed/NCBI
|
|
8
|
Harbeck N, Schmitt M, Kates RE, Kiechle M,
Zemzoum I, Jänicke F and Thomssen C: Clinical utility of
urokinase-type plasminogen activator and plasminogen activator
inhibitor-1 determination in primary breast cancer tissue for
individualized therapy concepts. Clin Breast Cancer. 3:196–200.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang S, New L, Pan Z, Han J and Nemerow
GR: Urokinase plasminogen activator/urokinase- specific surface
receptor expression and matrix invasion by breast cancer cells
requires constitutive p38alpha mitogen-activated protein kinase
activity. J Biol Chem. 275:12266–12272. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Janicke F, Prechtl A, Thomssen C, Harbeck
N, Meisner C, Untch M, Sweep CGJF, Selbmann H-K, Graeff H and
Schmitt M: Randomized adjuvant chemotherapy trial in high-risk,
lymph node-negative breast cancer patients identified by
urokinase-type plasminogen activator and plasminogen activator
inhibitor type 1. J Natl Cancer Inst. 93:913–920. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Look MP: Pooled analysis of uPA and PAI-1
for prognosis in primary breast cancer patients. EORTC Receptor and
Biomarker Study Group. Int J Biol Markers. 15:70–72.
2000.PubMed/NCBI
|
|
12
|
Lee KS, Lee DH, Chun SY and Nam KS:
Metastatic potential in MDA-MB-231 human breast cancer cells is
inhibited by proton beam irradiation via the Akt/nuclear
factor-kappaB signaling pathway. Mol Med Rep. 10:1007–1012.
2014.PubMed/NCBI
|
|
13
|
Foote RL, Stafford SL, Petersen IA, Pulido
JS, Clarke MJ, Schild SE, Garces YI, Olivier KR, Miller RC, Haddock
MG, et al: The clinical case for proton beam therapy. Radiat Oncol.
7:1742012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alan Mitteer R, Wang Y, Shah J, Gordon S,
Fager M, Butter P-P, Jun Kim H, Guardiola-Salmeron C,
Carabe-Fernandez A and Fan Y: Proton beam radiation induces DNA
damage and cell apoptosis in glioma stem cells through reactive
oxygen species. Sci Rep. 5:139612015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Narang H, Kumar A, Bhat N, Pandey BN and
Ghosh A: Effect of proton and gamma irradiation on human lung
carcinoma cells: Gene expression, cell cycle, cell death,
epithelial-mesenchymal transition and cancer-stem cell trait as
biological end points. Mutat Res. 780:35–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee KS, Shin JS and Nam KS: Effect of
proton beam irradiation on the regulation of metastasis-enhancing
factors in MCF-7 human breast cancer cells. J Korean Phys Soc.
63:1373–1378. 2013. View Article : Google Scholar
|
|
17
|
Lee KS, Shin JS, Shon YH and Nam KS:
Anti-angiogenic activity in metastasis of human breast cancer cell
irradaited by a proton beam. J Korean Phys Soc. 61:268–272. 2012.
View Article : Google Scholar
|
|
18
|
Miller FR: Tumor subpopulation
interactions in metastasis. Invasion Metastasis. 3:234–242.
1983.PubMed/NCBI
|
|
19
|
Miller FR, Miller BE and Heppner GH:
Characterization of metastatic heterogeneity among subpopulations
of a single mouse mammary tumor: Heterogeneity in phenotypic
stability. Invasion Metastasis. 3:22–31. 1983.PubMed/NCBI
|
|
20
|
Lee KB, Lee JS, Park JW, Huh TL and Lee
YM: Low energy proton beam induces tumor cell apoptosis through
reactive oxygen species and activation of caspases. Exp Mol Med.
40:118–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jermann M: Particle therapy statistics in
2014. Int J Particle Ther. 2:50–54. 2015. View Article : Google Scholar
|
|
22
|
Lee KS, Mo JY, Shon YH and Nam KS:
Inhibition of metastatic activities in human breast cancer cells
irradiated by a proton beam. J Korean Phys Soc. 59:653–656. 2011.
View Article : Google Scholar
|
|
23
|
Pulaski BA and Ostrand-Rosenberg S: Mouse
4T1 breast tumor model. Curr Protoc Immunol. Chapter 20(Unit 20):
222001. View Article : Google Scholar
|
|
24
|
Nieves-Alicea R, Colburn NH, Simeone AM
and Tari AM: Programmed cell death 4 inhibits breast cancer cell
invasion by increasing tissue inhibitor of metalloproteinases-2
expression. Breast Cancer Res Treat. 114:203–209. 2009. View Article : Google Scholar :
|
|
25
|
Wang M, Hada M, Saha J, Sridharan DM,
Pluth JM and Cucinotta FA: Protons sensitize epithelial cells to
mesenchymal transition. PLoS One. 7:e412492012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heerboth S, Housman G, Leary M, Longacre
M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor
metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wallerand H, Cai Y, Wainberg ZA, Garraway
I, Lascombe I, Nicolle G, Thiery J-P, Bittard H, Radvanyi F and
Reiter RR: Phospho-Akt pathway activation and inhibition depends on
N-cadherin or phospho-EGFR expression in invasive human bladder
cancer cell lines. Urol Oncol. 28:180–188. 2010. View Article : Google Scholar
|
|
28
|
Bailey JM, Singh PK and Hollingsworth MA:
Cancer metastasis facilitated by developmental pathways: Sonic
hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem.
102:829–839. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kundu N and Fulton AM: Selective
cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic
disease in a murine model of breast cancer. Cancer Res.
62:2343–2346. 2002.PubMed/NCBI
|
|
30
|
Morita Y, Hata K, Nakanishi M, Nishisho T,
Yura Y and Yoneda T: Cyclooxygenase-2 promotes tumor
lymphangiogenesis and lymph node metastasis in oral squamous cell
carcinoma. Int J Oncol. 41:885–892. 2012.PubMed/NCBI
|
|
31
|
Kang JH, Song KH, Jeong KC, Kim S, Choi C,
Lee C and Oh S: Involvement of Cox-2 in the metastatic potential of
chemotherapy-resistant breast cancer cells. BMC Cancer. 11:3342011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stillfried GE, Saunders DN and Ranson M:
Plasminogen binding and activation at the breast cancer cell
surface: The integral role of urokinase activity. Breast Cancer
Res. 9:R142007. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Cremoux P, Grandin L, Dieras V,
Savignoni A, Degeorges A, Salmon R, Bollet MA, Reyal F,
Sigal-Zafrani B, Vincent-Salomon A, et al: Urokinase-type
plasminogen activator and plasminogen-activator-inhibitor type 1
predict metastases in good prognosis breast cancer patients.
Anticancer Res. 29:1475–1482. 2009.PubMed/NCBI
|
|
34
|
Andres SA, Edwards AB and Wittliff JL:
Expression of urokinase-type plasminogen activator (uPA), its
receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas
and their clinical relevance. J Clin Lab Anal. 26:93–103. 2012.
View Article : Google Scholar : PubMed/NCBI
|
